Myrelez (Lanreotide Acetate)

Lanreotide acetate mimics natural somatostatin and binds to somatostatin receptors, primarily sst2 and sst5, on endocrine and tumor cells. This binding blocks intracellular signaling pathways that stimulate hormone release and cell proliferation, thereby lowering growth hormone levels and inhibiting tumor growth.

The dosage of Myrelez is individualized by the prescribing clinician based on the patient’s condition, response, and tolerance. The prescriber determines the appropriate amount, frequency, and duration of subcutaneous administration according to current clinical guidelines.

Safety data for lanreotide acetate in pregnancy and lactation are limited. It should be used only if the potential therapeutic benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks with their healthcare provider.

To request Myrelez, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Myrelez (lanreotide acetate) and other agents such as octreotide share a similar mechanism of receptor binding but differ in formulation, dosing frequency, and pharmacokinetic profile. Lanreotide is often administered as a long‑acting injectable every 4–8 weeks, which may offer greater convenience compared with shorter‑acting alternatives.

Myrelez must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. If temporary storage at room temperature is unavoidable, limit exposure to no more than 30 minutes and return the product to refrigeration promptly.

Myrelez is given by subcutaneous injection, typically into the abdomen or thigh. The injection is performed by a trained healthcare professional or, after appropriate instruction, by the patient or caregiver using the supplied pre‑filled syringe or autoinjector device.

Serious risks include gallbladder disease or cholelithiasis, acute pancreatitis, severe allergic reactions such as anaphylaxis, significant hyperglycemia that may require medical treatment, and rare cardiac arrhythmias. Patients should be monitored regularly for these events, and therapy should be stopped if they occur.

Myrelez is contraindicated in patients with known hypersensitivity to lanreotide acetate or any of the formulation excipients. Caution is advised in individuals with severe hepatic or renal impairment, uncontrolled diabetes, or a history of gallbladder disease, and it should be avoided in pregnancy unless clearly justified.